Dr. Iftikhar-ul-Haq Tareen, FCPS.
Prof. Azizur Rahman, MCPS, FCPS.
Pak J Med Sci. 2013 Jul;29(4):1018-22. doi: 10.12669/pjms.294.3735.
To evaluate the efficacy of primary intra vitreal bevacizumab (IVB) injection on macular edema in diabetic patients with improvement in best corrected visual acuity (BCVA) and central macular thickness (CMT) on optical coherence tomography (OCT).
This prospective interventional case series study was conducted at Retina Clinic, Al-Ibrahim Eye Hospital, and Isra Postgraduate Institute of Ophthalmology Karachi. Between December 2010 to June 2012. BCVA measurement with Early Treatment in Diabetic Retinopathy Study (ETDRS) charts and ophthalmic examination, including Slit-lamp bio microscopy, indirect ophthalmoscopy, Fundus fluorescein angiography (FFA) and OCT were done at the base line examination. At monthly interval all patients were treated with 3 injections of 0.05 ml intra vitreal injection containing 1.25 mg bevacizumab. Patients were followed up for 6 months and BCVA and OCT were taken at the final visit at 6 month.
The mean BCVA at base line was 0.42±0.14 Log Mar units. This improved to 0.34±0.13, 0.25±0.12, 0.17±0.12 and 0.16±0.14 Log Mar units at 1 month after 1(st), 2(nd) 3(rd) injections and at final visit at 6 months respectively, a difference that was statistically significant (P>0.0001) from base line. The mean 1mm CMT measurement was 452.9 ± 143.1 µm at base line, improving to 279.8 ± 65.2 µm (P<0.0001) on final visit. No serious complications were observed.
Primary IVB at a dose of 1.25 mg on monthly interval seems to provide stability and improvement in BCVA and CMT in patient with DME.
评估原发性玻璃体内贝伐单抗（IVB）注射治疗糖尿病黄斑水肿的疗效，通过光学相干断层扫描（OCT）评估最佳矫正视力（BCVA）和中心黄斑厚度（CMT）的改善情况。
这是一项在卡拉奇的 Al-Ibrahim 眼科医院和 Isra 眼科研究所的视网膜诊所进行的前瞻性干预性病例系列研究。研究时间为 2010 年 12 月至 2012 年 6 月。在基线检查时，使用早期糖尿病视网膜病变研究（ETDRS）图表和眼科检查进行 BCVA 测量，包括裂隙灯生物显微镜、间接检眼镜、眼底荧光血管造影（FFA）和 OCT。所有患者每月接受 3 次 0.05ml 玻璃体内注射，每 0.05ml 注射含有 1.25mg 贝伐单抗。患者随访 6 个月，在第 6 个月的最后一次就诊时进行 BCVA 和 OCT 检查。
基线时的平均 BCVA 为 0.42±0.14 Log Mar 单位。在第 1、2、3 次注射后 1 个月和第 6 个月的最后一次就诊时，分别改善至 0.34±0.13、0.25±0.12、0.17±0.12 和 0.16±0.14 Log Mar 单位，与基线相比差异具有统计学意义（P>0.0001）。基线时平均 1mm CMT 测量值为 452.9±143.1µm，在最后一次就诊时改善至 279.8±65.2µm（P<0.0001）。未观察到严重并发症。
每月间隔给予 1.25mg 的原发性 IVB 似乎可以为 DME 患者提供 BCVA 和 CMT 的稳定性和改善。
